Trader consensus prices "No" at 84.5% for a new COVID variant of concern before 2027, driven by WHO and ECDC assessments showing no SARS-CoV-2 strains currently meeting VOC criteria—increased transmissibility, severity, or vaccine escape—as of late March 2026. The recent BA.3.2 "Cicada" variant, a highly mutated Omicron descendant spreading in over 30 U.S. states and 30 countries since early 2026, remains only a variant under monitoring, with low prevalence (under 0.2% of sequences), no evidence of worse outcomes, and preserved vaccine effectiveness against severe disease. Stable low test positivity (3.4% in March) and high population immunity from boosters reinforce this skin-in-the-game view, though ongoing genomic surveillance could shift odds if Cicada or emerging sublineages escalate.